Superworth

Novavax EPS NVAX

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$1.54
Latest quarter, Q2 FY26
−$0.32
−152% on a year earlier
Fiscal year 2025
$2.39

Novavax's earnings per share was −$1.54 over the twelve months to Jun 30, 2026, down 168% on a year earlier.

In its latest quarter, Q2 FY26, it was −$0.32, down 152% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$2.39n/a
FY2024−$1.33n/a
FY2023−$5.53n/a
FY2022−$8.40n/a
FY2021−$23.29n/a
FY2020−$6.79n/a
FY2019−$5.67n/a
FY2018−$4.97n/a
FY2017−$0.63n/a
FY2016−$1.03n/a
FY2015−$0.59n/a
FY2014−$0.36n/a
FY2013−$0.31n/a
FY2012−$0.22n/a
FY2011−$0.17n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.32−152%−$1.54
Q1 FY26−$0.06−102%−$0.60
Q4 FY25$0.09n/a$2.39
Q3 FY25−$1.25n/a$1.79
Q2 FY25$0.62−37%$2.28
Q1 FY25$2.93n/a$2.65
Q4 FY24−$0.51n/a−$1.33
Q3 FY24−$0.76n/a−$2.26
Q2 FY24$0.99+71%−$2.76
Q1 FY24−$1.05n/a−$3.17
Q4 FY23−$1.44n/a−$5.53
Q3 FY23−$1.26n/a−$6.37

Against its peers

Companies in Biotechnology nearest Novavax's size, closest first, today.

CompanyEPS, 12 monthsGrowth
NVAXNovavax−$1.54−168% a year
VCELVericel$0.46+283% a year
ADMAAdma Biologics$0.70−18% a year
MGTXMeiraGTx$0.71
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
PLXProtalix BioTherapeutics$0.23+283% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
Peer median$0.94

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Novavax

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.